Oncology

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

Oncology pharmacists can share advocacy tips, craft elevator pitches, and use virtual Capitol Hill days to boost patient access and cancer care.

Oncology pharmacists discuss the transformative role of bispecific antibodies in treating relapsed/refractory multiple myeloma, addressing challenges and patient care strategies.

Circulating tumor cell PD-L1 liquid biopsy guides PD-1 therapy in lung cancer, helping oncology pharmacists predict response and monitor disease in real time.

Experts discuss the importance of optimizing immunotherapy for advanced NSCLC, enhancing treatment selection and patient care.

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

Tagraxofusp monotherapy in myelofibrosis shows symptom relief with manageable toxicity, as pharmacists can monitor capillary leak syndrome and cytopenias.

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

New clinical findings highlight promising strategies for treating aggressive central nervous malignancies.

Expanded Medicaid coverage has been linked to access to early diagnosis, timely treatment, and continuity of care in breast cancer.

The safety of IV push iron sucrose amid shortages and breakthroughs in BCMA bispecifics and menin inhibitors reshape myeloma and leukemia care.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatment.

Explore the balance of ambition and self-care in cancer care, emphasizing curiosity, collaboration, and the importance of sustainable productivity.

Amivantamab with lazertinib emerges as a promising frontline therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.

Patients need evidence that reflects real benefit.

Explore emerging evidence on aspirin’s potential role in reducing cancer risk and improving survival.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

GDF15 can reshape prostate cancer prognosis and treatment; pharmacists track emerging biomarker panels and targeted therapies for metastatic disease.

H. pylori requires diagnosis, antibiotic- and acid-suppression-based therapy, and post-treatment eradication confirmation to prevent gastritis and cancer.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

Oncology pharmacists use MammaPrint to target anthracyclines in high-risk breast cancer, sparing others cardiotoxicity and severe nausea.

FDA approval expands pembrolizumab (Keytruda) for PD‑L1+ platinum‑resistant ovarian cancer, pairing with paclitaxel ± bevacizumab to improve survival outcomes.

RESTORE trial data show investigational elritercept improves myelofibrosis anemia and cytopenias, reduces transfusions, and guides pharmacists on monitoring with ruxolitinib.